欧盟接受赛诺菲承诺以结束贬低竞品疫苗的反垄断调查,赛诺菲免于罚款
STAT+: Sanofi avoids fine as EU accepts offer to end antitrust probe over disparaging rival vaccine
欧盟委员会接受赛诺菲提出的承诺,结束对其贬低竞品流感疫苗宣传行为的反垄断调查,赛诺菲因此免于罚款。欧委会此前指出,赛诺菲在主要面向德国和法国医护人员的宣传中,将 CSL Seqirus 的 Fluad 疫苗描述为劣于其自家 Efluelda 疫苗,且赛诺菲在这两国占据主导地位。赛诺菲承诺开展更正性宣传并今后不再有此类行为,该协议具有法律约束力。
![]()
By Ed Silverman
Oct. 14, 2026
Pharmalot Columnist, Senior Writer
Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter.
European Union antitrust regulators accepted concessions from Sanofi to settle an investigation into an allegedly “misleading” campaign that disparaged the only rival flu vaccine recommended for vulnerable patients at risk for developing the illness. In doing so, the company avoided being fined.
The European Commission had suggested that Sanofi portrayed the Fluad vaccine marketed by CSL Seqirus as inferior to its own Efluelda vaccine in a communication campaign that primarily targeted health care professionals in Germany and France. Sanofi holds a dominant position in both countries, according to the EC.
To resolve the probe, Sanofi committed to a corrective communication campaign rectifying its “possible disparaging behavior” and to refrain from such behavior in the future, according to Teresa Riberta, the European Commission executive vice president for Clean, Just and Competitive Transition. The agreement is legally binding.
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
来源:STAT 主站 · statnews.com